Placeholder Banner

BIO Statement on Patient Access to Medicines

September 21, 2015
"As a general policy, BIO does not comment on matters related to individual company products or product pricing decisions, such as today’s news about Turing Pharmaceuticals. That said, the focus of the biotechnology industry is to develop innovative therapies and cures for patients. This means it is imperative not only that we develop these new medicines, but that all patients have access to them, as necessary to meet their healthcare needs. This principle should apply to old medicines as much as to the new."